Solid Tumors Clinical Trials

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors  

APT-008 is an open-label, Phase I/Ib, dose escalation and expansion cohort study to evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and preliminary efficacy of EOS301984 as monotherapy and in combination with other anticancer therapies in participants with advanced solid tumors.

None

A Study to Evaluate the Safety and Efficacy of Image Guided Surgery using Indocyanine Green for Intramolecular Imaging of Solid Tumors Compared to Standard of Care (TumorGlow) (PRIME)

Indocyanine Green (ICG) is an FDA approved, water-soluble tricarbocyanine dye routinely used in clinical settings for measuring cardiac output, liver function, and retinal angiography and has been in use for over 50 years. Patient diagnosed with solid tumor cancers have a high rate of recurrence when surgery is a treatment. …

UPCC 03920: A Phase 1/1b Open-label Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors

Subjects may receive TPST-1120 alone or in combination with nivolumab. Subjects eligible to participate are those with advanced solid tumors.

UPCC 18920: A Phase 1 First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors

0.0

A Phase 1 Open-Label Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …

UPCC 22918: A Phase 1 Study Exploring the Safety Tolerability Pharmacokinetics and Pharmacodynamics of INCB086550 in Participants with Advanced Solid Tumors

The purpose of this Study is to test the safety and tolerability of the INCB086550 and to find out what effects, if any, the INCB086550 has on people and their cancer. The INCB086550 has been tested in animals but not yet in people. This Study will test different doses of …

UPCC 11917: A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

Request for collaborative review: WIRB serving as IRB of record.

UPCC 07917: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

TBD

UPCC 23217: A Phase 1b/2 Study ofBMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors

TBD